Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.76 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.76 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158522 | 1.00 | PTGER4 (0.76) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5812669 | 1.00 | PTGER4 (0.76) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4374909 | 0.94 | PTGER4 (0.68) | PTGER4PTGER3PTGER2 | |
| SCHEMBL14268653 | 0.94 | PTGER4 (0.68) | PTGER4PTGER3PTGER2 | |
| SCHEMBL2209602 | 0.94 | PTGER4 (0.68) | PTGER4PTGER3PTGER2 | |
| SCHEMBL13766272 | 0.93 | PTGER4 (0.67) | PTGER4PTGER3PTGER2 | |
| SCHEMBL14307456 | 0.92 | PTGER4 (0.66) | PTGER4PTGER3PTGER2 | |
| SCHEMBL13204801 | 0.90 | PTGER4 (0.63) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4994629 | 0.89 | PTGER4 (0.71) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4994622 | 0.89 | PTGER4 (0.71) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503984-B1 | 8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-03-20 | — | — | EP | claimed |
| EP-1503984-A1 | 8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| US-20040254230-A1 | Method for treating ocular hypertension | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | US | claimed |
| EP-1461026-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| US-20040157912-A1 | 8-Azaprostaglandin analogs as agents for lowering intraocular pressure | OLD DAVID W (US) | 2004-08-12 | — | — | US | claimed |
| US-20030220506-A1 | 8-Azaprostaglandin analogs as agents for lowering intraocular pressure | OLD DAVID W (US) | 2003-11-27 | — | — | US | claimed |
| WO-2003097596-A1 | 8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2003-11-27 | — | — | WO | claimed |
| EP-1110949-B1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PROD INC (US) | 2003-09-24 | — | — | EP | claimed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | claimed |
| US-6573294-B1 | Method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound | ALLERGAN, INC. | 2003-06-03 | — | — | US | claimed |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O'KEEFE (US) | 2002-04-04 | — | — | US | claimed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | claimed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | claimed |
| EP-1503984-B1 | 8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-03-20 | — | — | EP | disclosed |
| US-6906097-B2 | 8-azaprostaglandin analogs as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1503984-A1 | 8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220506-A1 | 8-Azaprostaglandin analogs as agents for lowering intraocular pressure | PTGIR, PTGIS, PTGS1 | PTGER4 34/4885PTGER3 15/4885PTGER2 17/4885 |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
| US-20040157912-A1 | 8-Azaprostaglandin analogs as agents for lowering intraocular pressure | PTGIR, PTGIS, PTGS1 | PTGER4 34/4885PTGER3 15/4885PTGER2 17/4885 |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 4/4885PTGER2 3/4885 |
| US-20040254230-A1 | Method for treating ocular hypertension | PTGIR, PTGER4, PTGER1 | PTGER4 2/4885PTGER3 5/4885PTGER2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.